Lapchak v. Paradigm Biopharmaceuticals (USA), Inc.

District Court, S.D. California·Decided August 5, 2025·No. 3:24-cv-00143·Unknown

Opinion

1 2 3 4 5 6 7 10 11 PAUL A. LAPCHAK, an individual, Case No.: 24-CV-143 JLS (DDL)

12 Plaintiff, ORDER GRANTING DEFENDANTS’ 13 v. MOTION TO DISMISS

(ECF No. 19) (USA), INC., a Delaware corporation; and 15 DONNA SKERRETT, an individual, 16 Defendants. 17

18 Presently before the Court are Defendants Paradigm Biopharmaceuticals (USA), 19 Inc. (“Paradigm”) and Donna Skerrett’s (“Skerrett”) (collectively, “Defendants”) Motion 20 to Dismiss Plaintiff’s Second Amended Complaint’s First and Second Causes of Action 21 (“Mot.,” ECF No. 19) and Memorandum of Points and Authorities in Support Thereof 22 (“Mem.,” ECF No. 19-1). Plaintiff Paul A. Lapchak (“Plaintiff”) filed an Opposition to 23 the Motion (“Opp’n,” ECF No. 20), to which Defendants submitted a Reply (“Reply,” ECF 24 No. 21. The Court took this matter under submission without oral argument pursuant to 25 Civil Local Rule 7.1(d)(1) on June 27, 2025. ECF No. 22. Having carefully considered 26 the Parties’ arguments, Plaintiff’s Second Amended Complaint (“SAC,” ECF No. 18), and 27 the law, the Court GRANTS Defendants’ Motion to Dismiss. 28 / / / 2 I. Procedural Background 3 Plaintiff initiated this action by filing a Complaint against Defendants on January 4 22, 2024. See ECF No. 1. Plaintiff filed his First Amended Complaint (“FAC”) on March 5 28, 2024, alleging four causes of action: (1) breach of contract against all Defendants; 6 (2) breach of fiduciary duties against Skerrett; (3) violation of “California Whistleblower 7 Statute” against all Defendants; and (4) violations of “California employment law” against 8 all Defendants. ECF No. 4 (“FAC”). Subsequently, Defendants filed a Motion to Dismiss 9 Plaintiff’s First, Second, and Fourth Causes of Action for failure to state a claim upon 10 which relief can be granted. See generally ECF No. 9. 11 On February 7, 2025, the Court granted Defendants’ Motion and dismissed 12 Plaintiff’s First, Second, and Fourth Cause of Action. See ECF No. 15 (“FAC Order”) at 9. 13 However, the dismissal was without prejudice and the Court granted Plaintiff leave to 14 amend his complaint. See FAC Order at 18–19. 15 On April 29, 2025, Plaintiff filed a Second Amended Complaint (“SAC,” ECF 16 No. 18). Plaintiff’s SAC now alleges seven causes of action: (1) breach of contract against 17 both Defendants; (2) violation of “California Whistleblower Statute” against both 18 Defendants; (3) violation of California Labor Code § 204 against Paradigm, (4) violation 19 of California Labor Code § 203 against Paradigm; (5) violation of California Labor Code 20 § 226 against Paradigm; (6) retaliation in violation of public policy against Paradigm; 21 (7) and retaliation under California Labor Code § 98.6 against Paradigm. See generally 23 On May 13, 2025, Defendants filed a Motion to Dismiss (1) the First Cause of Action 24 as to Defendant Skerrett only, and (2) the Second Cause of Action for Whistleblower 25 Violations as to both Defendants. See Mot. On June 12, 2025, Plaintiff filed an Opposition. 26 See Opp’n. And on June 18, 2025, Defendants filed their Reply. See Reply. 27 / / / 28 / / / 1 II. Second Amended Complaint: Plaintiff’s Allegations 2 Plaintiff Paul Lapchak, a San Diego, California resident, is a renowned scientist with 3 a PhD in Pharmacology. SAC ¶¶ 1, 8. Plaintiff was hired by Paradigm, a Delaware 4 corporation that develops and sells drug formulas, to be its executive, holding the title of 5 “Global Head of Translational Development,” on or about October 7, 2022. Id. ¶¶ 2, 9, 11. 6 Plaintiff and Paradigm entered into a contract, the “Employment Agreement,” which 7 required Paradigm to provide certain financial compensation and Paradigm shares to 8 Plaintiff as part of the employment inducement. Id. ¶¶ 24, 25. Plaintiff was an executive 9 for approximately 12 months, and his last performance evaluation indicated he “exceeded 10 on all measures of performance.” Id. ¶ 10. On or about October 3, 2023, Paradigm sent 11 Plaintiff a new employment agreement that had not been negotiated with him, and which 12 “materially altered several aspects of the parties’ agreed-upon contractual relationship.” 13 Id. ¶ 12. On or about October 10, 2023, Plaintiff protested the changes and stated he would 14 not enter into the new agreement. Id. ¶ 13. 15 Plaintiff is also a shareholder in Paradigm and shares promised to him have not been 16 timely provided, as set forth in his Employment Agreement. Id. ¶ 14. For example, his 17 “sign on bonus” of 25,000 shares were due October 24, 2022, and were not timely provided. 18 Id. ¶ 15. His one-year anniversary 100,000 shares were due October 24, 2023, and were 19 also not timely provided. Id. ¶ 16. On October 29, 2023, Paradigm issued a “trading halt” 20 and issued a “rights offer” or “entitlement offer” to its employees, and Plaintiff timely 21 exercised his entitlement/rights offer as to the missing 125,000 shares of Paradigm stock. 22 Id. ¶ 17. Plaintiff has not received the 125,000 shares to which he is entitled, nor other 23 shares to which he is entitled under a capital raise. Id. ¶ 18. He indicates Defendant 24 Skerrett, “is a person responsible for Paradigm’s failure to pay Lapchak wages under 25 California law.” Id. ¶ 31. 26 One of the drugs Paradigm currently develops is a pentosan polysulfate sodium 27 (“PPS”), an “FDA-approved drug that has a long track record of safely treating 28 inflammation for over 60 years.” Id. ¶ 11. Paradigm’s primary focus, per Plaintiff, is to 1 develop PPS (under the name of Zilosul®) to treat osteoarthritis. Id. 2 On November 1, 2023, at a company-wide team meeting, Plaintiff “presented an 3 overview of drug toxicity of PPS or Zilosul.” Id. ¶ 20. Then on November 17, 2023, 4 Plaintiff “presented a power point deck to Paradigm’s safety officer, director of clinical 5 operations, and head of osteoarthritis[,] summarizing significant multi-organ toxicity of 6 Paradigm’s drug product, PPS or Zilosul.” Id. ¶ 20. Plaintiff proceeded to inform the 7 regulatory department of the multi-organ toxicity of the same product. Id. Subsequently, 8 purportedly retaliating against Plaintiff’s actions, Defendants disabled Plaintiff’s access to 9 the workplace computers. Id. ¶ 21. After Plaintiff protested, Defendants purportedly 10 “falsely claimed” Plaintiff was still an employee. Id. ¶ 21. Defendants formally terminated 11 Plaintiff on or about January 12, 2024. Id. ¶ 22. 13 Rule 12(b)(6) permits a party to raise by motion the defense that the complaint 14 “fail[s] to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). The 15 Court evaluates whether a complaint states a cognizable legal theory and sufficient facts in 16 light of Federal Rule of Civil Procedure 8(a), which requires a “short and plain statement 17 of the claim showing that the pleader is entitled to relief.” “[A] plaintiff’s obligation to 18 provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and 19 conclusions, and a formulaic recitation of the elements of a cause of action will not do.” 20 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (alteration in original). 21 To survive a 12(b)(6) motion, then, “a complaint must contain sufficient factual 22 matter . . . to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 23 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). A claim is facially plausible 24 when the facts pled “allow[] the court to draw the reasonable inference that the defendant 25 is liable for the misconduct alleged.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Lapchak v. Paradigm Biopharmaceuticals (USA), Inc., (S.D. Cal. 2025).

Lapchak v. Paradigm Biopharmaceuticals (USA), Inc. (Lapchak v. Paradigm Biopharmaceuticals (USA), Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Yale Simons v. United States
497 F.2d 1046 (Ninth Circuit, 1974)
Karen L. Edwards v. Occidental Chemical Corporation
892 F.2d 1442 (Ninth Circuit, 1990)
John Desoto v. Yellow Freight Systems, Inc.
957 F.2d 655 (Ninth Circuit, 1992)
Michael Lacey v. Joseph Arpaio
693 F.3d 896 (Ninth Circuit, 2012)
Reno v. Baird
957 P.2d 1333 (California Supreme Court, 1998)
Grisham v. Philip Morris, Inc.
670 F. Supp. 2d 1014 (C.D. California, 2009)
People v. DePriest
163 P.3d 896 (California Supreme Court, 2007)
Arias v. Dyncorp
928 F. Supp. 2d 10 (District of Columbia, 2013)
Applied Underwriters, Inc. v. Larry Lichtenegger
913 F.3d 884 (Ninth Circuit, 2019)
Wi-Lan Inc. v. LG Elecs., Inc.
382 F. Supp. 3d 1012 (S.D. California, 2019)
Ferretti v. Pfizer Inc.
855 F. Supp. 2d 1017 (N.D. California, 2012)
Dowell v. Contra Costa County
928 F. Supp. 2d 1137 (N.D. California, 2013)